CL2023001085A1 - Constructos de fusión de anticuerpos que se acoplan a células nk - Google Patents
Constructos de fusión de anticuerpos que se acoplan a células nkInfo
- Publication number
- CL2023001085A1 CL2023001085A1 CL2023001085A CL2023001085A CL2023001085A1 CL 2023001085 A1 CL2023001085 A1 CL 2023001085A1 CL 2023001085 A CL2023001085 A CL 2023001085A CL 2023001085 A CL2023001085 A CL 2023001085A CL 2023001085 A1 CL2023001085 A1 CL 2023001085A1
- Authority
- CL
- Chile
- Prior art keywords
- antigen
- cells
- cd16a
- binding
- engage
- Prior art date
Links
- 210000000822 natural killer cell Anatomy 0.000 title abstract 3
- 230000004927 fusion Effects 0.000 title 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 abstract 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 abstract 3
- 102000025171 antigen binding proteins Human genes 0.000 abstract 2
- 108091000831 antigen binding proteins Proteins 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 101100334515 Homo sapiens FCGR3A gene Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La invención se refiere a proteínas multiespecíficas de unión al antígeno que se acoplan a células natural killer (NK) para desencadenar la citotoxicidad de células NK al acoplarse al CD16A (FcyRIIIA) expresado en células NK, en donde la proteína de unión al antígeno comprende al menos dos porciones de unión al antígeno CD16A y al menos una porción de unión al antígeno diana adicional. La porción de unión al antígeno CD16A comprende regiones variables de la cadena liviana y cadena pesada ligadas una después de la otra en una cadena de polipéptido y la región variable en el terminal N de la cadena de polipéptido que comprende la porción de unión al antígeno CD16A es una región variable de la cadena liviana.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18167384 | 2018-04-13 | ||
| EP18167385 | 2018-04-13 | ||
| EP18190661 | 2018-08-24 | ||
| EP18190662 | 2018-08-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001085A1 true CL2023001085A1 (es) | 2023-10-06 |
Family
ID=66625219
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002625A CL2020002625A1 (es) | 2018-04-13 | 2020-10-09 | Constructos de fusión de anticuerpos que se acoplan a células nk. |
| CL2023001085A CL2023001085A1 (es) | 2018-04-13 | 2023-04-14 | Constructos de fusión de anticuerpos que se acoplan a células nk |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002625A CL2020002625A1 (es) | 2018-04-13 | 2020-10-09 | Constructos de fusión de anticuerpos que se acoplan a células nk. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11001633B2 (es) |
| EP (1) | EP3774914A2 (es) |
| JP (1) | JP2021521275A (es) |
| KR (1) | KR20200143436A (es) |
| CN (3) | CN113817066A (es) |
| AU (1) | AU2019252970A1 (es) |
| BR (1) | BR112020020828A2 (es) |
| CA (1) | CA3095373A1 (es) |
| CL (2) | CL2020002625A1 (es) |
| CO (1) | CO2020014167A2 (es) |
| CR (1) | CR20200549A (es) |
| IL (1) | IL277925A (es) |
| MA (1) | MA52227A (es) |
| MX (1) | MX2020010728A (es) |
| PE (1) | PE20201346A1 (es) |
| PH (1) | PH12020551664A1 (es) |
| RU (1) | RU2022105827A (es) |
| SG (1) | SG11202010064QA (es) |
| TW (1) | TW202012441A (es) |
| WO (1) | WO2019198051A2 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4034245A1 (en) * | 2019-09-25 | 2022-08-03 | Universität Stuttgart | Trivalent binding molecules |
| WO2021116277A1 (en) * | 2019-12-10 | 2021-06-17 | Institut Pasteur | New antibody blocking human fcgriiia and fcgriiib |
| EP4081554A1 (en) | 2019-12-27 | 2022-11-02 | Affimed GmbH | Method for the production of bispecific fcyriii x cd30 antibody construct |
| AU2021357841A1 (en) | 2020-10-08 | 2023-06-15 | Affimed Gmbh | Trispecific binders |
| EP4240415A1 (en) * | 2020-11-08 | 2023-09-13 | Seagen Inc. | Combination-therapy antibody drug conjugate with immune cell inhibitor |
| CN116783217A (zh) * | 2020-12-03 | 2023-09-19 | 安进公司 | 具有多个结合结构域的免疫球蛋白构建体 |
| JP2024516230A (ja) | 2021-04-30 | 2024-04-12 | ジェネンテック， インコーポレイテッド | がんのための治療及び診断方法並びに組成物 |
| CN116574190A (zh) * | 2021-07-30 | 2023-08-11 | 启愈生物技术(上海)有限公司 | 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用 |
| EP4376958A1 (en) | 2021-07-30 | 2024-06-05 | Affimed GmbH | Duplexbodies |
| CN113929785B (zh) * | 2021-09-10 | 2023-05-23 | 钦元再生医学(珠海)有限公司 | 一种可自分泌pd1-trem2双特异性抗体的嵌合抗原受体免疫细胞及其应用 |
| WO2023049909A1 (en) * | 2021-09-24 | 2023-03-30 | Synergy Imt, Inc. | Composition of recombinant antigen binding molecules and method of making and using thereof |
| CA3233696A1 (en) | 2021-11-03 | 2023-05-11 | Joachim Koch | Bispecific cd16a binders |
| CA3237018A1 (en) | 2021-11-03 | 2023-05-11 | Joachim Koch | Bispecific cd16a binders |
| CN116284385A (zh) * | 2021-12-07 | 2023-06-23 | 信达细胞制药(苏州)有限公司 | 靶向bcma的p329g抗体及其与嵌合抗原受体细胞的组合和应用 |
| CN114349869B (zh) * | 2021-12-20 | 2023-09-26 | 上海恩凯细胞技术有限公司 | 一种双特异性的nk细胞激动剂及制备方法和应用 |
| WO2024027828A1 (en) * | 2022-08-05 | 2024-02-08 | Chimagen Biosciences, Ltd | Multi-specific antibodies targeting a dimerizable tumor antigen and an immunostimulatory antigen |
| US20240092909A1 (en) * | 2022-09-14 | 2024-03-21 | Ibio, Inc. | Pd-1 agonist antibodies |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837242A (en) | 1992-12-04 | 1998-11-17 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2301971A1 (en) | 2001-02-20 | 2011-03-30 | ZymoGenetics, L.L.C. | Antibodies that bind both BCMA and TACI |
| GB0510790D0 (en) * | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| NZ612647A (en) | 2009-03-10 | 2015-03-27 | Biogen Idec Inc | Anti-bcma antibodies |
| EP2361936B1 (en) * | 2010-02-25 | 2016-04-20 | Affimed GmbH | Antigen-binding molecule and uses thereof |
| KR101972446B1 (ko) | 2011-05-27 | 2019-04-25 | 글락소 그룹 리미티드 | Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）결합 단백질 |
| TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| EP2825557B1 (en) | 2012-03-16 | 2017-06-28 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Soluble engineered monomeric fc |
| CN104736174B (zh) * | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| EP2914628A1 (en) | 2012-11-01 | 2015-09-09 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| ES2667420T3 (es) | 2013-02-05 | 2018-05-10 | Engmab Sàrl | Anticuerpos biespecíficos contra cd3epsilon y bcma |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | Moléculas de unión para bcma y cd3 |
| CA2903056A1 (en) * | 2013-03-15 | 2014-09-18 | Merck Patent Gmbh | Tetravalent bispecific antibodies |
| WO2015109131A2 (en) * | 2014-01-15 | 2015-07-23 | Zymeworks Inc. | Bi-specific cd3 and cd19 antigen-binding constructs |
| AU2015369831B2 (en) * | 2014-12-22 | 2019-07-11 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
| BR112017015136A2 (pt) * | 2015-01-14 | 2018-01-30 | Compass Therapeutics Llc | polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, construto de ligação ao antígeno imunomodulador multiespecífico, conjugado, composição farmacêutica, método para tratar um indivíduo com câncer, método para inibir ou reduzir o crescimento de câncer, composição, célula, método de fazer um polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, vetor ou conjunto de vetores e kit |
| EP3091031A1 (en) * | 2015-05-04 | 2016-11-09 | Affimed GmbH | Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor |
| CA3219372A1 (en) * | 2015-05-04 | 2016-11-10 | Affimed Gmbh | Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy |
| WO2016207278A1 (en) * | 2015-06-23 | 2016-12-29 | Innate Pharma | Multispecific nk engager proteins |
| CA2995754A1 (en) * | 2015-08-17 | 2017-02-23 | Janssen Pharmaceutica Nv | Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof |
| EP3156417A1 (en) * | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
| CN105367660B (zh) * | 2015-12-22 | 2018-12-21 | 深圳市北科生物科技有限公司 | 一种抗cd16a抗原和抗muc1抗原的双特异性抗体 |
| CN106632681B (zh) * | 2016-10-11 | 2017-11-14 | 北京东方百泰生物科技有限公司 | 抗egfr和抗cd3双特异抗体及其应用 |
| DK3589655T3 (da) * | 2017-02-28 | 2022-11-28 | Affimed Gmbh | Tandem diabody til cd16a målrettet nk-celle optagelse |
-
2019
- 2019-04-12 RU RU2022105827A patent/RU2022105827A/ru unknown
- 2019-04-12 CN CN202111125475.XA patent/CN113817066A/zh active Pending
- 2019-04-12 AU AU2019252970A patent/AU2019252970A1/en active Pending
- 2019-04-12 WO PCT/IB2019/053040 patent/WO2019198051A2/en active Application Filing
- 2019-04-12 KR KR1020207032435A patent/KR20200143436A/ko unknown
- 2019-04-12 CA CA3095373A patent/CA3095373A1/en active Pending
- 2019-04-12 SG SG11202010064QA patent/SG11202010064QA/en unknown
- 2019-04-12 CN CN202111125559.3A patent/CN113880952A/zh active Pending
- 2019-04-12 MA MA052227A patent/MA52227A/fr unknown
- 2019-04-12 CR CR20200549A patent/CR20200549A/es unknown
- 2019-04-12 BR BR112020020828-0A patent/BR112020020828A2/pt unknown
- 2019-04-12 MX MX2020010728A patent/MX2020010728A/es unknown
- 2019-04-12 CN CN201980033176.8A patent/CN112119097B/zh active Active
- 2019-04-12 EP EP19725409.7A patent/EP3774914A2/en active Pending
- 2019-04-12 JP JP2021504593A patent/JP2021521275A/ja active Pending
- 2019-04-12 PE PE2020001584A patent/PE20201346A1/es unknown
- 2019-04-15 TW TW108113068A patent/TW202012441A/zh unknown
- 2019-12-13 US US16/714,396 patent/US11001633B2/en active Active
-
2020
- 2020-10-08 PH PH12020551664A patent/PH12020551664A1/en unknown
- 2020-10-09 CL CL2020002625A patent/CL2020002625A1/es unknown
- 2020-10-11 IL IL277925A patent/IL277925A/en unknown
- 2020-11-12 CO CONC2020/0014167A patent/CO2020014167A2/es unknown
-
2021
- 2021-04-20 US US17/235,854 patent/US20210253698A1/en active Pending
-
2023
- 2023-04-14 CL CL2023001085A patent/CL2023001085A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN112119097B (zh) | 2021-10-15 |
| WO2019198051A2 (en) | 2019-10-17 |
| CO2020014167A2 (es) | 2021-04-08 |
| MX2020010728A (es) | 2020-11-06 |
| PE20201346A1 (es) | 2020-11-25 |
| IL277925A (en) | 2020-11-30 |
| BR112020020828A2 (pt) | 2021-01-19 |
| CN112119097A (zh) | 2020-12-22 |
| US20200109202A1 (en) | 2020-04-09 |
| CA3095373A1 (en) | 2019-10-17 |
| US11001633B2 (en) | 2021-05-11 |
| WO2019198051A3 (en) | 2019-11-14 |
| CN113817066A (zh) | 2021-12-21 |
| CN113880952A (zh) | 2022-01-04 |
| CR20200549A (es) | 2021-03-18 |
| KR20200143436A (ko) | 2020-12-23 |
| RU2022105827A (ru) | 2022-04-05 |
| SG11202010064QA (en) | 2020-11-27 |
| AU2019252970A1 (en) | 2020-11-26 |
| TW202012441A (zh) | 2020-04-01 |
| JP2021521275A (ja) | 2021-08-26 |
| MA52227A (fr) | 2021-04-21 |
| US20210253698A1 (en) | 2021-08-19 |
| EP3774914A2 (en) | 2021-02-17 |
| PH12020551664A1 (en) | 2021-12-13 |
| CL2020002625A1 (es) | 2021-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023001085A1 (es) | Constructos de fusión de anticuerpos que se acoplan a células nk | |
| CO2019003945A2 (es) | Proteínas de fusión heterodiméricas biespecíficas que contienen proteínas de fusión fc il-15/il-15rα y fragmentos de anticuerpo pd-1 | |
| AR112419A1 (es) | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos | |
| PE20190514A1 (es) | Proteinas de union de tipo anticuerpo biespecificas que se unen especificamente a cd3 y cd123 | |
| EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| CO2020010345A2 (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d | |
| EA201390146A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| PE20120549A1 (es) | Proteinas biespecificas de union a antigenos | |
| CU20190087A7 (es) | Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1 | |
| PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| ES2639026T3 (es) | Anticuerpos totalmente humanos específicos para CADM1 | |
| EA201491575A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| PE20230381A1 (es) | Proteina de union a rgma | |
| NI201800113A (es) | Anticuerpos anti-basigin humanizados y uso de los mismos. | |
| AR114102A1 (es) | Anticuerpo biespecífico heterodimérico estructural natural anti-pd-1 / anti-her2 y método para su preparación | |
| MY198370A (en) | Proteins specific for baff and b7rp1 | |
| AR118355A1 (es) | Métodos de fabricación para producir composiciones de anticuerpos anti-tnf | |
| BR112016019332A2 (pt) | anticorpo pai-1 anti-humano inovador | |
| AR099604A1 (es) | Anticuerpos de metaloproteinasa de matriz 9 y sus métodos de uso | |
| AR076083A1 (es) | Anticuerpo monoclonal anti-rhesus d | |
| AU2018292438A1 (en) | Stabilized chimeric fabs | |
| EA202090581A1 (ru) | Продукты слияния транстиретина и иммуноглобулина | |
| AR117192A1 (es) | ANTICUERPO BIESPECÍFICO HETERODIMÉRICO SIMILAR EN ESTRUCTURA AL ANTICUERPO NATURAL ANTI-TNFa / ANTI-IL-17A, Y MÉTODO PARA SU PREPARACIÓN | |
| PE20240690A1 (es) | Anticuerpos split que se unen a celulas cancerosas y dirigen radionuclidos a dichas celulas | |
| EA202091973A1 (ru) | Конструкции слитых белков, содержащие анти-muc1 антитело и il-15 |